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Abstract
Doublecortin-like (DCL) is a microtubule-binding protein crucial for neuroblastoma (NB) cell proliferation. We have
investigated whether the anti-proliferative effect of DCL knockdown is linked to reduced mitochondrial activity. We
found a delay in tumor development after DCL knockdown in vivo in doxycycline-inducible NB tumor xenografts. To
understand the mechanisms underlying this tumor growth retardation we performed a series of in vitro experiments in
NB cell lines. DCL colocalizes with mitochondria, interacts with the mitochondrial outer membrane protein OMP25/
SYNJ2BP and DCL knockdown results in decreased expression of genes involved in oxidative phosphorylation.
Moreover, DCL knockdown decreases cytochrome c oxidase activity and ATP synthesis. We identified the C-terminal
Serine/Proline-rich domain and the second microtubule-binding area as crucial DCL domains for the regulation of
cytochrome c oxidase activity and ATP synthesis. Furthermore, DCL knockdown causes a significant reduction in the
proliferation rate of NB cells under an energetic challenge induced by low glucose availability. Together with our
previous studies, our results corroborate DCL as a key player in NB tumor growth in which DCL controls not only
mitotic spindle formation and the stabilization of the microtubule cytoskeleton, but also regulates mitochondrial
activity and energy availability, which makes DCL a promising molecular target for NB therapy.
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Introduction
Neuroblastoma (NB) is the most commonly diagnosed
cancer in infants [1] and the most frequent solid extracranial
neoplasm in children under five years of age [2,3]. NB origins
from neural crest cells, which are the precursors of the
sympathetic nervous system [4]. With the currently available
therapies the survival rate of patients with advance stage NB
remains below 50% [5]. Great efforts have been done towards
a more effective and less toxic therapy for NB. These efforts
include the identification of novel molecular targets that play a
crucial role in NB tumorigenic processes, such as proliferation,
alternative energy metabolism, relative (acquired) resistance to
apoptosis, angiogenesis and/or metastasis [6,7,8].
We have previously proposed the Doublecortin-like kinase
(DCLK1) gene as an attractive molecular target for NB therapy
[7,9]. DCLK-derived proteins belong to doublecortin (DCX)
family and include the microtubule associated proteins (MAPs)
DCLK-long and doublecortin-like (DCL). DCL and DCLK-long
are highly expressed in neuroblasts and are vital for neuroblast
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proliferation, migration and differentiation [10,11]. Silencing of
DCLK-derived MAPs results in cell-cycle arrest and apoptosis
in NB cells [9,11].
Structurally, DCL exhibits high amino acid sequence identity
with DCX in both the two microtubule-binding domains (DCX-
domains) and their C-terminal serine/proline (S/P)-rich domain
[12]. Because of their DCX-domains, DCLK-derived MAPs play
a role in microtubule stabilization and mitotic spindle formation
[10,11]. In addition, aided by protein-protein interactions via its
S/P-rich domain, DCL interacts with several proteins and is
involved in the intracellular transport of glucocorticoid receptors
in neuronal progenitor cells and NB cells [13,14].
We have shown that DCL is highly expressed in human NB
and glioma tumors [9]. Moreover, we found a high correlation
between DCL expression and the expression of genes related
to mitochondrial activity in human NBs. Surprisingly, gene
expression profiling after DCLK-derived MAPs knockdown in
NB cells indicated that mitochondria were among the most
affected cellular components. Moreover, oxidative
phosphorylation (OXPHOS) and oxidative stress were among
the most affected biological process, suggesting an additional
role for DCL in the regulation of the energy metabolism [9].
Mitotic stimuli result in the activation of mitochondrial
bioenergetics by transcriptional activation of mitochondrial
genes and induction of intracellular signaling pathways [15,16].
Cell proliferation is associated with increased rates of
mitochondrial OXPHOS and glycolysis [17]. Both processes
generate energy in the form of adenosine triphosphate (ATP)
and biochemical intermediates for de novo biosynthesis of
macromolecules [17,18]. These energetic pathways have been
proposed as potential therapeutic targets for cancer therapy
[19,20,21,22].
In this study, we investigate the effect of DCL knockdown on
tumor growth in an in vivo NB xenograft model as well as on
mitochondrial activity in NB cells. Our data show a key role of
DCL in NB tumor development and in energy supply of NB
cells, a function that has not been reported for the DCLK1 gene
or any other member of the DCX family.
Materials and Methods
Reagents and antibodies
The mouse monoclonal antibody against α-tubulin was
purchased from Sigma-Aldrich Chemie B.V (Zwijndrecht, The
Netherlands) and the secondary antibody anti-mouse-HRP
from Tube-bio B.V. (Bevelandseweg, The Netherlands). A
recently developed primary rabbit antibody targeting the DCL-
specific sequence QRDLYRPLSSDDLDSVG-C was used [23].
Alexa Fluor® 488 goat anti-rabbit IgG, Alexa Fluor® 488
donkey anti-rabbit IgG and Alexa Fluor® 594 goat anti-mouse
IgG were from Molecular Probes (Leiden, The Netherlands).
The anti-rabbit-HRP antibody was from Santa Cruz (Tebu-Bio,
Heerhugowaard, The Netherlands). 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) was obtained from Sigma-Aldrich Chemie BV
(Zwijndrecht, The Netherlands). 5 mg/milliliter MTT in
phosphate-buffered saline (PBS, Life Technologies, Europe
BV, Bleiswijk, The Netherlands) was freshly prepared before
each determination. Doxycycline (Dox) and G418 were
purchased from Sigma-Aldrich Chemie B.V (Zwijndrecht, The
Netherlands). Dithiothreitol (DTT) was obtained from Sigma-
Aldrich Chemie BV (Zwijndrecht, The Netherlands) and the
Complete Protease Inhibitor Cocktail Tablets from Roche
Diagnostics Nederland BV (Almere, The Netherlands).
Cell culture and doxycycline treatment
Mouse N1E-115 neuroblastoma (NB) cells and African green
monkey kidney COS-1 cells were cultured as previous
described [9,11]. Doxycycline (Dox)-inducible NB stable cell
lines were cultured in the presence of 500 µg/ml G418. The
development of the Dox-inducible NB stable cell lines from
N1E-115 was described by Verissimo et al. 2010 [9]. These
cells (shDCL-2 or shDCL-3), in the presence of 1 µg/ml Dox,
express a shRNA against DCL [9]. The shDCL-2 cell line
expresses the shRNA with the sequence 5’-TCC-CGC-TGG-
TCA-TCC-TGC-ATC-TTG-TTT-CAA-GAG-AAC-AAG-ATG-
CAG-GAT-GAC-CAG-CTT-TTT-A-3’ and the complementary
sequence is 5’-CGC-GTA-AAA-AGC-TGG-TCA-TCC-TGC-
ATC-TTG-TTC-TCT-TGA-AAC-AAG-ATG-CAG-GAT-GAC-
CAG-C-3’. The sequence of the shRNA expressed in shDCL-3
cell line is 5’-TCC-CGG-TCA-TCC-TGC-ATC-TTG-TTG-TTT-
CAA-GAG-AAC-AAC-AAG-ATG-CAG-GAT-GAC-CTT-TTT-
A-3’ and 5’-CGC-GTA-AAA-AGG-TCA-TCC-TGC-ATC-TTG-
TTG-TTC-TCT-TGA-AAC-AAC-AAG-ATG-CAG-GAT-GAC-
C-3’. In addition, we have developed a negative control (NC)
NB Dox-inducible stable cell line from N1E-115 as described
previously [9]. A scramble shRNA nucleotide sequence was
cloned in pINV-7 vector (TaconicArtemis GmbH, Cologne,
Germany) as previously described [24]. The NC stable cell line
expresses a scramble shRNA with the sequence 5’-TCC-CGC-
TGT-CGC-TCT-TTC-GAG-TTT-ATT-CAA-GAG-ATA-AAC-
TCG-AAA-GAG-CGA-CAG-CTT-TTT-A-3’ and complementary
sequence 5’-CGC-GTA-AAA-AGC-TGT-CGC-TCT-TTC-GAG-
TTT-ATC-TCT-TGA-ATA-AAC-TCG-AAA-GAG-CGA-CAG-
C-3’. The Dox-inducible NB stable cells were treated with 1
µg/ml Dox or vehicle (Veh, milli-Q water) for 72 hours. We used
high glucose (4.5 g/L) DMEM medium to keep the Dox-
inducible NB cells in culture. For the challenge assay, low (1
g/L) glucose DMEM medium (Life Technologies, Europe BV,
Bleiswijk, The Netherlands) was used.
Transfection
For recovering DCL expression in Dox-inducible NB stable
cells that were in the presence of 1 µg/ml Dox for 72 hours, we
transfected these cells with 125 ng pcDNA3.1 vector
(Invitrogen, Breda, The Netherlands) containing the nucleotide
sequence for DCL full-length [11] or pcDNA3.1 empty plasmid
using lipofectamine 2000 (Invitrogen, Breda, The Netherlands)
following the manufacturer’s instructions. In addition, the
medium with Dox was replaced by medium with vehicle (milli-Q
water). Forty-eight hours after transfection, cell proliferation
was investigated or the cells were harvested for western blot,
cytochrome c activity or ATP synthesis assays. Using
TransIT®-COS Transfection kit (Mirus Bio LLC, Madison, WI),
COS-1 cells were transfected with one of the different DCL
truncations subcloned into pDsRed2-N1 vector as described
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previously [13]. The DCL truncations were generated from
DCL-DsRed2-N1 by PCR [13]. The primers used are indicated
in Table S1.
RNA isolation and quantitative real-time PCR
Cells were harvested and the RNA was isolated using TRIzol
reagent (Invitrogen, Breda, The Netherlands) according to the
manufacturer’s specifications. The RNA concentration and
purity were determined using a NanoDrop spectrophotometer
(NanoDrop products, Wilmington, DE). Quantitative real-time
PCR (RT-qPCR) was performed using ABI Prism 7900HT
Sequence Detection system (Applied Biosystems, Foster City,
CA) according to the manufacturer’s instructions. Messenger
RNA expression of Cox7c (Mm01545088_g1), Cox6a2
(Mm00438295_g1), Ndufa1 (Mm00444593_m1), Ndufa13
(Mm00445751_m1), Ncl (Mm00834059_g1), Nenf
(Mm00840262_m1), Pttg1 (Mm00479224_m1) and S100a6
(Mm00771682_g1) was analyzed using a target-specific assay
(Assays-on-demand Gene expression system; Applied
Biosystems). The expression levels were normalized to 18S
rRNA (Hs99999901_s1, Applied Biosystems). shRNA
expression was detected using Applied Biosystems custom
TaqMan® small RNA Assay and following the manufacturer’s
instructions (Applied Biosystems, Foster City, CA). The target
sequence for shDCL-2 was 5’-
ACAAGAUGCAGGAUGACCAGC-3’, for shDCL-3 was 5’-
ACAACAAGAUGCAGGAUGACC-3’ and for scramble shRNA
(NC) was 5’-AUAAACUCGAAAGAGCGACAGC-3’. The
expression levels were normalized to snoRNA202 (Applied
Biosystems).
Western blot analysis
Protein lysates, SDS-PAGE, and western blotting were
performed as described by Vreugdenhil et al [11]. The
expression of DCL was normalized to α-tubulin. Analysis and
quantification of the relative optical densities were performed
using ImageJ software [25].
Cell proliferation assay
Cell proliferation and survival were determined using the
colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide (MTT) assay as described previously [26], with some
modifications. In brief, N1E-115 cell lines were seeded in 96-
well culture plates at a seeding density of 3000 cells/well. 72
hours after treating the cells with 1 µg/ml Dox or Veh, 0.83
mg/ml MTT solution was added, and the cells were incubated
for 4 hours at 37°C, 5% CO2. Afterwards, the medium with MTT
was removed and 100 µl of DMSO was added to each well for
solubilization of formazan crystals. The optical density was
measured at 540 nm with a reference wavelength of 630 nm,
using a FLUOstar Optima plate reader (BMG LABTECH
GmbH, Offenburg, Germany).
Ethics statement and xenograft tumors assay
Animal experiments were approved by the Local Committee
for Animal Health, Ethics and Research of Leiden University
and conducted in accordance with the European Communities
Council Directive 86/609/EEC. Eight-week-old female BALB/c
athymic nude mice (Charles River Laboratories, Cologne,
Germany), five mice per group, were injected subcutaneously
into the right flank with 1 x 106 cells (one of the Dox-inducible
NB stable cell lines) using 25-G needles. Cells were
resuspended in 100 µl PBS. Three days following cell
inoculation, Dox-diet, 200 mg/kg doxycycline (Plexx BV, Elst,
The Netherlands) was provided or the mice continued receiving
the control diet (Plexx BV, Elst, The Netherlands). Tumor
growth was monitored by caliper and mice were weighted
every three days. Tumor volume was calculated as previously
described [27]. At day 14, animals were euthanized and tumors
were extracted.
Immunohistochemistry
Tumor tissue was formalin fixed and paraffin embedded.
Four micrometer sections were stained with H&E or subjected
to immunohistochemistry. Sections were deparaffinized,
rehydrated through an alcohol gradient to water, and subjected
to heat-induced antigen retrieval in 0.01 M citrate buffer pH 6.0
for 10 minutes. Endogenous peroxide activity was blocked with
1.5% (v/v) peroxide in methanol for 30 minutes at room
temperature and nonspecific binding was blocked with 2% (v/v)
normal horse serum (Vector Labs) or 2% (w/v) bovine serum
albumin (Sigma Aldrich) in PBS for 30 minutes. Sections were
incubated overnight at 4°C with rabbit polyclonal antibody Ki67
(Novocastra Laboratories Ltd, Newcastle, United Kingdon),
with cleaved caspase-3 (Asp175) (5A1E) rabbit mAb (Cell
Signaling Technologies, Leiden, The Netherlands) or with anti-
α-tubulin mouse mAb (Sigma-Aldrich Chemie BV, Zwijndrecht,
The Netherlands). The secondary antibodies Alexa Fluor® 488
donkey anti-rabbit and Alexa Fluor® 594 goat anti-mouse were
incubated for one hour at room temperature. Tissue was
counterstained with 1:10000 Hoechst for 5 minutes. Mouse
N1E-115 cells were grown for 72 hours in cover slips coated
with 200 ng/µl poly-L-lysine (Sigma-Aldrich Chemie B.V,
Zwijndrecht, The Netherlands). Cells were incubated for 30
minutes at 37°C in DMEM medium containing 100 nM
MitoTraker Orange CMTM Rosamine (Molecular Probes,
Leiden, The Netherlands). Subsequently, N1E-115 cells were
washed three times for five minutes with PBS-Tween 20 and
fixed with methanol-EGTA (97:3). Next, 4% freshly prepared
paraformaldehyde in PBS was added to the cells for 10
minutes. After three washes with PBS-Tween 20, cells were
permeabilized and blocked with TBP (1% Triton-x-100, 1%
bovine serum albumin (BSA) in PBS) for 1 hour at room
temperature. Cells were incubated with the rabbit monoclonal
anti-DCL antibody (1:500) for one hour. Following three times
wash with PBS-Tween 20, Alexa Fluor® 488 goat anti-rabbit
IgG (Life Technologies, Europe BV, Bleiswijk, The
Netherlands) was added for one hour at room temperature.
Nuclei were stained with 1:10000 Hoescht (Life Technologies,
Europe BV, Bleiswijk, The Netherlands) for five minutes.
Immunofluorescence and laser-scanning confocal
microscopy
Immunofluorescence and laser-scanning microscopy in Dox-
inducible NB stable cell lines from N1E-115 neuroblastoma
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cells and in African green monkey kidney COS-1 cells was
performed as previously described [13]. and using Leica TCS
SP8 confocal laser scanning microscope. COS-1 cells were
transfected with different DCL fragments subcloned into
pDsRed2-N1 vector as described previously [13]. EZ-Viewer
software (Nikon Instruments, Europe BV, Amstelveen, The
Netherlands), Leica application suite advanced fluorescence
software (LAS AF, Leica Microsystems B.V., Rijswijk, The
Netherlands) and ImageJ [25], were used for image analysis
and protein co-localization studies. Quantification of
colocalization score for DCL and mitochondria in stable NB
cells was performed as described previously [13].
Caspase-3 activity
Caspase-3 activity assay was performed as described
previously [9].
Yeast two-hybrid screen
The yeast 2-hybrid screen was performed with a Mouse
Adult Brain_RP1 ULTImate Y2HTM Library and the bait CARP/
ANIA-4 (GI:5468526) cloned into pB27 (N-LexA-CARP-C)
(Hybrigenics-Services, Paris, France). CARP/ANIA-4 is a 55
amino acid peptide that covers the 50 C-terminal amino acids
of DCL [28]. 79.3 million possible interactions were screened
and a proteome-wide interaction map (PIM) biological score
(Global PBS) were used to classify interactions into confidence
categories [29,30].
Mitochondria isolation
Mitochondria were isolated as described previously [31] with
some modifications. NB cells were harvested using trypsin
(GIBCO, Invitrogen BV) and spun down at 1500 rpm for 5
minutes. Pellet was washed with DMEM medium and,
subsequently with cold PBS. Cells were resuspended in 200 µl
mitobuffer (20 mM HEPES pH 7.5, 250 mM sucrose, 1 mM
EGTA, 1 mM EDTA, 10 mM KCl, 1.5 mM MgCl2, 1 mM DTT,
protein inhibitor cocktail tablet (1 table per 10 ml mitobuffer)
and nuclease free water) and lysed by sonication. The lysate
were centrifuged at 3000 rpm for 20 minutes at 4°C and the
supernatant was then spun down at 11000 rpm for 20 minutes
at 4°C. The pellet that contains the mitochondria was washed
once with mitobuffer and spun down at 11000 rpm.
Subsequently, the pellet was resuspended in 200µl Enzyme
Assay Buffer (Mitochondria Activity Assay kit, Bio-Connect BV,
Huissen, The Netherlands) and stored at -80°C.
Cytochrome C Oxidase Activity assay
The activity of cytochrome C Oxidase was measured in
isolated mitochondria from Dox-inducible NB cells treated with
1 µg/ml Dox or vehicle (Veh, milli-Q water) for 72 hours. The
measurements were performed in agreement with the advised
procedure from Mitochondria Activity Assay (Cytochrome C
Oxidase Activity assay) Kit (Bio-Connect BV, Huissen, The
Netherlands). In short, we measured the reduction in
absorption at the wavelength of 550 nm using UV/Vis UV-1700
PharmaSpec spectrophotometer (Shimadzu, Benelux BV,
Hertogenbosch, The Netherlands) at different time points (5,
15, 25, 35 and 45 seconds). Samples were normalized to the
amount of protein, which was determined using Pierce BCA
protein assay (Thermo, Fisher Scientific, Landsmeer, The
Netherlands). Furthermore, results were normalized for
membrane integrity of the outer mitochondrial membrane
(Cytochrome C Oxidase Activity Kit, Bio-Connect BV, Huissen,
The Netherlands).
ATP fluorescent assay
72 hours after 1 µg/ml Dox or Veh treatment, NB cells with
inducible DCL knockdown were harvested and lysed using ATP
Assay Buffer from the Colorimetric/Fluorometric Assay Kit (ITK
Diagnostics BV, Uithoorn, The Netherlands). ATP levels were
detected by a fluoremetric assay following the instructions
described in Colorimetric/Fluorometric Assay (ITK Diagnostics
BV, Uithoorn, The Netherlands) and using Viktor2 Multilabel
plate reader. Results were normalized to the amount of protein
that was determined performing Pierce BCA protein assay
(Thermo, Fisher Scientific, Landsmeer, The Netherlands).
Statistical analysis
Unless otherwise indicated, results presented are
representative of three independent experiments run in
triplicates. Student’s t-test and two-way ANOVA were carried
out using GraphPad Prism 4.00 (GraphPad software, La Jolla,
USA) and SPSS statistical software version 16.0 (SPSS Inc.,
Chicago, IL, USA). P values smaller than 0.05 were considered
statistically significant. Results are expressed as mean ±
standard error of the mean (s.e.m.).
Results
Validation of DCL silencing in Doxycycline (Dox)-
inducible NB stable cell lines and effects on NB
proliferation
In order to further investigate the role of DCL in NB
proliferation we used the recently developed Dox-inducible NB
stable cell lines that express shRNAs targeting specifically DCL
(shDCL-2 and shDCL-3) [9]. For the present study we
developed a Dox-inducible NB stable cell line expressing a
scrambled shRNA as negative control (NC; Materials and
methods). After induction with Dox, all inducible NB stable cell
lines expressed significantly more shRNA (P<0.001) than cells
treated with vehicle (Veh, Figure 1A). No shRNA was detected
in the parental NB cell line (N1E-115). The expression of the
specific shRNAs resulted in significant DCL knockdown (85.6 ±
2.1% and 76.7 ± 1.5% knockdown in shDCL-2 and shDCL-3,
respectively) while no effect on DCL expression was detected
in the NC cell line, as compared to the Veh-treated cells, non-
induced control (Figure 1B, C). In agreement with low shRNA
expression in vehicle-treated cells (Figure 1A), we detected
that DCL expression was significantly downregulated in Veh-
treated shDCL-2(P<0.01) and shDCL-3(P<0.001) compared to
NC cells, although to a much lesser extent (Figure 1B, C). This
reduction in DCL expression levels, in the absence of Dox
induction, did not result in any significant effect in cell
proliferation. However, treatment with Dox (1 µg/ml, 72 hours)
DCL in Mitochondrial Activity and NB Tumor Growth
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resulted in significant reductions in cell proliferation in shDCL-2
and shDCL-3 (P<0.01, vs. Veh-treated cells) but not in NC cells
(Figure 1D). In agreement with our previous observations in NB
cell lines transiently transfected with synthetic siRNAs [9],
these results indicate that high levels of DCL knockdown are
required to reduce cell proliferation. Consistently, a panel of
four proliferation-related genes [32,33,34,35] nucleolin (Ncl),
neudesin (Nenf), pituitary tumor-transforming 1 (Pttg1) and
S100 calcium binding protein A6 (S1006) was found
downregulated only after Dox-induced DCL knockdown in
shDCL-2 and shDCL-3 cell lines (Figure S1). These genes
were also found differently expressed in NB cells with DCLK-
derived MAPs knockdown [9].
DCL silencing results in a significant reduction in NB
tumor growth
To study the possible effect of DCL downregulation in NB
cells on tumor growth in vivo, we developed a mouse NB
xenograft model, using the Dox-inducible cell lines shDCL-2
and shDCL-3 (Materials and methods). We observed a
significant increase in shRNA expression in tumors after Dox
induction (200 mg per kg of diet, 14 days), while shRNAs were
below detection levels in tumors from Veh-treated animals
(Figure S2). Subsequently, we detected a significant reduction
in DCL expression in tumors after Dox-induced shRNA
expression (61.3 ± 9.9% and 77.6 ± 7.1% DCL knockdown in
Dox-induced shDCL-2 and shDCL-3 respectively, relative to
Veh-treated groups). No significant differences were observed
in DCL expression between tumors present in animals
xenografted with NC, shDCL-2, and shDCL-3 and fed with Veh-
diet (Figure 2A, B).
Cell proliferation within the tumor tissue was assessed by
immunofluorescence to detect the proliferation marker Ki67
(Figure 2C, D). A significantly reduction (P<0.05) in the
numbers of Ki67 positive cells was detected only in Dox-treated
shDCL-3 tumors. A similar trend was observed in Dox-treated
shDCL-2 tumors, although the differences were not statistically
significant (Figure 2C, D). Interestingly, a significant increased
(P<0.05) in cleaved caspase-3 expression was observed in
Dox-treated shDCL-2 and shDCL-3 tumors (Figure 2E, F).
These results are in agreement with our previous observations
that silencing of DCL in NB cells in vitro results in induction of
apoptotic cell death [9].
Furthermore, treatment of xenografted animals with Dox (200
mg per kg of diet, 14 days) resulted in a significant reduction in
tumor volume after Dox-induced shDCL-2 (F1,7 = 5.953;
P<0.05) and shDCL-3 (F6,30 = 27.95; P<0.001) expression
compared to veh-treatment (Figure 3A, B). Animals
xenografted with NC cells did not present significant
differences (F1,8 = 0.002; P=0.969) in tumor volume after Dox
or Veh treatment (Figure 3C). We identified a significant
reduction in tumor volume from day 12 onwards in animals
xenografted with Dox-induced shDCL-2(P<0.05) or
shDCL-3(P<0.01) expressing cells (Figure 3D). Moreover, the
first detectable tumors appear at day 9 in Veh-treated groups
and at day 12 in Dox-treated groups (Figure 3A, B), suggesting
a significant delay in growth in the tumors with reduced
amounts of DCL protein. We did not observe any significant
difference in body weight arising from Dox or Veh treatment in
any experimental group (Figure 4A, B). All tumors presented an
undifferentiated histology, necrotic areas and were highly
vascularized (Figure 4C and Figure S3).
DCL colocalizes with mitochondria and DCL
knockdown results in decreased expression of
mitochondrial-related genes in NB cells
To identify the mechanisms responsible for the effects of
DCL downregulation on tumor growth observed in vivo, we
performed a series of in vitro studies using the Dox-inducible
shDCL-2, shDCL-3 and NC cell lines. Mitochondria have been
shown to be crucial for tumor development [36] and our
previous studies identified a highly significant correlation
between DCL expression and mitochondrial-related genes [9].
Therefore, we have tested the hypothesis that DCL is involved
in the regulation of mitochondrial functioning in NB cell. For
this, we investigated possible DCL colocalization with
mitochondria and the effects of DCL downregulation on the
expression of a set of mitochondrial-related genes.
Previous studies predicted a mitochondrial location for DCL
[9]. In the present study we found a substantial colocalization
between DCL and mitochondria in NB cells (Figure 5 and
Figure S4). Using a mouse adult brain library in a yeast two-
hybrid screen, we found that the C-terminal domain of DCL
interacts with the mitochondria outer membrane protein 25
(OMP25)/ synaptojanin-2-binding protein (SYNJ2BP) [37]
(Table 1), consistent with the colocalization results shown in
Figure 5 and Figure S4. Interestingly, induction of DCL
downregulation by Dox treatment in shDCL-2 and shDCL-3
cells resulted in a significant reduction (P<0.05) in DCL/
mitochondria colocalization score (Figure S4). No significant
differences in colocalization score were found between Veh-
treated shDCL-2, shDCL-3 and NC cells and Dox-treated NC
cells (Figure S4). Further, we found significant downregulation
of the mitochondrial-related genes cytochrome c oxidase,
subunit VIIc (Cox7c); cytochrome c oxidase, subunit VIa
(Cox6a2) and NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 1 (Ndufa1) in both shDCL-2 and shDCL-3 NB
cells treated with Dox (P<0.01 or P<0.001, Figure 6A-C). In
addition, NADH dehydrogenase (ubiquinone) 1 alpha
subcomplex, 13 (Ndufa13 or GRIM-19) was significantly
downregulated in Dox-treated shDCL-2 cells, while a trend
towards less Ndufa13 expression was observed in Dox-treated
shDCL-3 cells (Figure 6D). These data suggests that DCL is
involved in mitochondrial activity regulation.
DCL regulates mitochondrial activity in NB cells
To test a DCL role in mitochondrial activity, we investigated
the activity of cytochrome c oxidase. Mitochondria isolated from
NB cells with Dox-induced DCL knockdown showed
significantly less cytochrome c oxidase activity (P<0.05 in
shDCL-2 and P<0.01 in shDCL-3, Figure 7A). Moreover, we
found that ATP synthesis was significantly inhibited (P<0.01)
after DCL knockdown in shDCL-2 and shDCL-3 cells (Figure
7B). Notably, transfection of shDCL-2 and shDCL-3 cells with a
shRNA resistant DCL plasmid (Materials and methods)
recovered DCL expression, cytochrome c oxidase activity and
DCL in Mitochondrial Activity and NB Tumor Growth
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ATP synthesis, suggesting that DCL is crucially involved in
controlling mitochondrial activity and energy production in NB
cells (Figure 7C-F).
Glucose restriction results in reduction of NB cell
proliferation after DCL downregulation
In the presence of oxygen, most cells produce energy from
glucose by OXPHOS in mitochondria. This OXPHOS-regulated
energy is crucial for cell proliferation [20,36]. Nevertheless,
many tumor cells, including NB, also process glucose by
Figure 1.  DCL knockdown in Dox-inducible NB cells results in less NB proliferation.  (A) shRNA expression in the different
NB cell lines treated with doxycycline (Dox) or vehicle (Veh) for 72 hours. (B) Western blotting results of DCL and α-tubulin
expression in Dox-inducible NB cells treated for 72 hours with doxycycline (Dox) or vehicle (Veh). (C) Quantification and
normalization of DCL expression to α-tubulin. (D) Cell proliferation 72 hours after starting adding Dox or Veh to the growth medium.
N1E-115 cells, mouse NB cell line used to develop the Dox-inducible NB cell lines. NC, negative control Dox-inducible NB cells.
shDCL-2 and shDCL-3, Dox-inducible NB cell lines that express shRNA against DCL. RQ, relative quantification. Error bars, s.e.m.
**, P<0.01; ***, P<0.001.
doi: 10.1371/journal.pone.0075752.g001
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Figure 2.  DCL knockdown in Dox-inducible NB tumors correlates with less proliferation and enhanced apoptosis.  (A) DCL
and α-tubulin expression in Dox-inducible tumors from nude mice treated with doxycycline- (Dox) or vehicle (Veh)-diet. (B) DCL
expression normalized to α-tubulin. (C) Immunostaining of Ki67 (green) positive cells in the Dox-inducible NB tumors. (D) Average
of positive Ki67 cells per high-power field (HPF). Immunostaining (E) and quantification (F) of cleaved caspase-3 positive cells
(green) per HPF. Images (C and E) are representative of the average expression of each group. For each section, 5-10 different
fields were analyzed. NC, negative control Dox-inducible NB tumors. shDCL-2 and shDCL-3, Dox-inducible NB tumors that express
shRNA targeting DCL. Blue, Hoechst staining. Red, α-tubulin staining. Arrows, examples of Ki67 positive cells (C) or cells with
cleaved caspase-3 (E). Error bars, s.e.m. *, P<0.05. Scale bars, 25 µm (C) or 50 µm (D).
doi: 10.1371/journal.pone.0075752.g002
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aerobic glycolysis [38,39]. In order to understand whether the
deficits in mitochondrial activity were associated with DCL
knockdown in NB cells, we exposed NB cells to glucose
restriction and analyzed the effects of DCL downregulation on
cell proliferation. Proliferation of shDCL-2 and shDCL-3 cells
was reduced under low glucose conditions (Figure 8A) with or
without Dox treatment. This effect was not observed in NC
cells. Importantly, proliferation was significantly inhibited by
DCL downregulation in both low and high glucose
environments (P<0.05, Figure 8A-D). We did not observe
significant differences in the low/high glucose proliferation ratio
in NC cells. However, Dox-treated shDCL-2 and shDCL-3 cells
presented a significantly reduced low/high glucose proliferation
ratio (P<0.05 in shDCL-2 and P<0.01 in shDCL-3, Figure 8E).
These results suggest that after DCL downregulation NB cells
proliferate less in an energy supply-restricted environment. To
support this conclusion, rescue of DCL expression in the Dox-
inducible cell lines results in a concomitant recovery of cell
proliferation. Interestingly, recovery of DCL expression also
resulted in a significant decrease in caspase-3 activity (Figure
S5).
S/P-rich and the second DCX-domains of DCL are
required for mitochondrial activity regulation
Previous studies have demonstrated that proteins derived
from the DCLK1 gene present microtubule binding-dependent
and independent functions [13,14]. Furthermore, results from
out yeast two-hybrid screen suggested that C-terminal domain
of DCL interacts with the mitochondria outer membrane
proteins (Table 1). In a primary effort to characterize the DCL
protein domains involved in regulation of mitochondrial activity,
we developed seven DCL mutants containing different
structurally relevant combinations of the two DCX-domains and
the C-terminal S/P-rich domain (Material and methods).
Subsequently, we induced their expression in COS-1 cells
(Figure S6) and studied the effect on microtubule bundling,
intracellular localization, cytochrome c oxidase activity and ATP
synthesis (Figure 9, Figure S7 and Table S2).
Figure 3.  DCL knockdown results in a delayed NB tumor growth.  The normalized tumor growth is shown for shDCL-2 (A),
shDCL-3 (B) and NC (C) tumors developed from the correspondent Dox-inducible NB cells lines injected subcutaneously in BALB/c
athymic nude mice. Tumor growth (A-C) was normalized to the maximum tumor size per group. (D) Average of tumor volume 9, 12
and 14 days after injecting the Dox-inducible NB cells. NC, negative control Dox-inducible NB tumors. shDCL-2 and shDCL-3, Dox-
inducible NB tumors that express shRNA against DCL. Error bars, s.e.m. *, P<0.05; **, P<0.01; ***, P<0.001.
doi: 10.1371/journal.pone.0075752.g003
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Interestingly, significantly increased (P<0.05) cytochrome c
oxidase activity and ATP synthesis was detected in COS-1
cells transfected with the full-length DCL (Figure 9). These
increases in cytochrome c activity and ATP synthesis were only
replicated by a mutant containing both the second DCX-domain
and the S/P-rich domain (Figure 9). No significant differences
in cytochrome c oxidase activity or ATP synthesis were
detected between cells transfected with the empty pDsRed2-
N1 vector and any other mutant (Figure 9A, B). Full-length DCL
overexpression in COS-1 cells induces strong DCL
colocalization to microtubules and microtubule bundling; most
of DCL’s known biological activities have been linked to this
property [10,11,13]. Therefore, we investigated the cellular
location and the microtubule bundling activity of the six DCL
mutants that we were able to express in COS-1 cells. We found
that the second DCX-domain and the linker between this
domain and the S/P-rich domain are the minimal domains
required for microtubule bundling (Figure S7).
Our preliminary characterization of the protein domains
required for regulation of mitochondrial activity indicated that
both the second DCX-domain and the S/P-rich domain are
necessary for this new biological activity of DCL. As the
presence of the second DCX-domain, the S/P-rich domain and
the short linker between these two domains are sufficient to
induce microtubule bundling in COS-1 cells, we conclude that
the regulation of mitochondrial activity may be linked to DCL’s
microtubule-binding activity.
Discussion
In the present study we show that downregulation of the
MAP DCL results in inhibition of neuroblastoma (NB) cell
proliferation in vitro and in delayed NB tumor development in
vivo. Further, we demonstrate that DCL colocalizes with
mitochondria, interacts with the mitochondrial outer membrane
protein SYNJ2BP/OMP25 and is involved in the regulation of
mitochondrial activity and ATP synthesis. Moreover, we map
this new biological activity to the C-terminal domains of the
DCL protein, specifically to DCL’s second DCX-domain and its
S/P rich domain. Therefore, our data reveal a novel function for
DCL, i.e. regulation of mitochondrial activity and ATP
synthesis, which may contribute to the regulation of NB tumor
growth.
We observed a significant delay in NB xenograft tumor
growth in mice with induced DCL knockdown. Recently, we and
others have shown that DCL is a crucial MAP for mitotic
Figure 4.  DCL silencing leads to smaller tumor formation with necrotic areas.  (A) Representative mice of the different groups
14 days after inoculation of the Dox-inducible NB cells. (B) Mice weight over time. (C) Tumor histology showing high vascularization
(arrows) and necrotic areas (* in blue). The quantification of the vascular structures and necrotic areas is shown in Figure S3. Error
bars, s.e.m. *, P<0.05. Scale bars, 50 µm.
doi: 10.1371/journal.pone.0075752.g004
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Figure 5.  DCL knockdown results in less mitochondrial
colocalization in NB cells.  DCL (green) and mitochondria
(red) staining in Dox-inducible NB cells treated with doxycycline
revealed less colocalization (yellow) in NB cells with DCL
knockdown (shDCL-2 and shDCL-3). Colocalization scores and
images of Dox-inducible NB cells treated with vehicle are
shown in Figure S4. Mitochondria were stained with 100 nM
MitoTraker Orange CMTM Rosamine. Blue, Hoechst staining.
NC, negative control Dox-inducible NB cell lines that express
scramble shRNA. shDCL-2 and shDCL-3, Dox-inducible NB
cell lines that express shRNA against DCL. Scale bars, 10 µm.
doi: 10.1371/journal.pone.0075752.g005
Table 1. Protein preys interacting with the C-terminal
domain of DCL in a yeast two-hybrid screen, using an adult
mouse brain library.
Protein Global PBS Clones SID Full length
Synj2bp A 5 1-145 145
Ap1m1 D 3 118-423 423
Gnl3l D 1 8-268 577
Zfp106 E 1 1420-1658 1888
Zfp521 E 4 51-225 1311
Note: The confidence in the interactions was categorized according to global PBS
scores. PBS A-D indicates very high, high, good and moderate confidence in the
interaction, respectively. E denotes highly connected protein domains (high
likelihood of artifacts). High confidence binding was observed to the outer
membrane mitochondria protein Synj2bp/OMP25 (PBS = A). Five independent
prey fragments (clones) identified the interaction, all encoding the full-length
Synj2bp protein of 145 amino acids. Moderate or highly connected interactions
were indicated to prey fragments matching four additional reference proteins (PBS
= D/E). Abbreviations: PBS, proteome-wide interaction map(PIM) biologic score;
SID, selected interaction domain (amino acid sequence) shared by all prey
fragments matching the same reference protein; Full length, number of amino
acids in reference protein.
doi: 10.1371/journal.pone.0075752.t001
spindle formation and stabilization and as such is vital for
neuroblast proliferation and migration [10,11]. Moreover, DCL
knockdown results in cell-cycle arrest and apoptosis in
neuroblasts and NB cells [9,10]. The results of the present
study indicate that DCL plays a role in NB tumorigenesis and
that DCL loss-of-function results in inhibition of NB proliferation
in vitro and in vivo.
Tumors with DCL knockdown were detected at a later time
point and remained significantly smaller than tumors
expressing higher DCL amounts. However, we did not observe
a complete arrest of tumor growth. It has been suggested that
long-term suppression of a certain gene/protein can result in
alternative and/or compensatory mechanisms that allow the
cells to proliferate [40,41]. This might be the reason why, even
when significantly delayed, we detected tumor development in
the presence of lower DCL expression levels. DCLK-long is
another MAP encoded by DCLK1 gene that plays a role in
microtubule stabilization and neuroblast proliferation [10,11].
Both DCL and DCLK-long are highly expressed in NB and in
glioblastoma [9], indicating that these MAPs play a role in the
development in these tumor types. Recent studies have shown
that DCLK1 is highly expressed in gastrointestinal stem cells
and it marks tumor stem cells that produce tumor progeny in
the polyps of Apc (Min/+) mice [42,43,44], suggesting an
important function for DCLK1 in colorectal cancer as well.
Overexpression of DCLK1 has also been detected in breast,
pancreas and prostate tumors [42,43,44]. Therefore, it would
be of great interest to further investigate whether or not DCLK-
long compensates for DCL knockdown and which potential
compensatory mechanisms were involved. This may allow
exploring new combinations of therapeutic approaches.
Previous studies have shown that combining silencing of
DCLK-derived MAPs with microtubule destabilizing agents,
such as vinca alkaloids, results in synergistic apoptotic effect
[45]. This may be an attractive approach to explore in vivo as
well. Moreover, in the present study, tumors that expressed
high levels of DCL revealed fewer apoptotic cells. This finding
is in agreement with previous reports in NB cell lines showing
that DCL knockdown leads to apoptotic cell death [9,45].
Because mitochondrial activity and energy production is of
high importance for cell proliferation and tumor growth
[17,46,47,48,49,50], we investigated the link between
mitochondrial regulation and DCL expression. We found a
significant downregulation of several mitochondrial-related
genes in NB cells with DCL knockdown which might result from
disruption of the mitotic spindles [10,11] and from the
disturbance of protein translocation to the nucleus through the
microtubules. Previous studies have shown that DCL regulates
the translocation of the glucocorticoid receptor (GR), a receptor
crucially involved in energy metabolism, to the nucleus in
neuronal progenitor cells and in neuroblastoma cells [13]. Once
in the nucleus, GR regulates the expression of several genes,
including mitochondrial-related genes [51]. In the present
study, besides the changes in gene expression, we have also
detected alterations in mitochondrial activity and reduction of
ATP synthesis after DCL knockdown, suggesting that DCL
plays a role in mitochondrial activity. These effects were
restored when we rescued DCL expression in NB cells with
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DCL knockdown. Moreover, we observed a clear DCL
colocalization with mitochondria and a direct interaction
between the C-terminal domain of DCL and the mitochondrial
outer membrane protein OMP25/ SYNJ2BP [37]. In line with
this are our previous data reporting DCL expression in human
NB tumors, which correlates significantly with the expression of
mitochondrial-related genes, including genes that are involved
in the oxidative phosphorylation (OXPHOS) process [9]. Also,
based on its primary amino acid sequence, DCL is predicted to
localize in mitochondria [9]. However, further research is
necessary to investigate whether DCL is indeed localized in
mitochondria, if it interacts with the integral mitochondrial outer
membrane protein OMP25/ SYNJ2BP and if that would be
related with the regulation of mitochondrial activity.
DCL may regulate NB tumor growth by linking stabilization of
mitotic spindles, mitosis of NB cells and mitochondrial activity.
It has been demonstrated that mitotic stimuli lead to the
activation of mitochondrial bioenergetic processes by
transcription activation of mitochondrial genes [15,16].
Proliferation in cancer cells has been associated with increased
rates of OXPHOS and glycolysis [17]. By exposing NB cells to
growth in low glucose conditions, we were able to observe that
NB cells with DCL knockdown were less able to cope with this
energetic challenge. This is in agreement with our results that
show less cytochrome c oxidase activity and lower ATP levels
synthesized by NB cells with DCL knockdown. Therefore, the
present data suggest that mitochondrial energy processing
pathways regulated by DCL are rate-limiting during NB
proliferation. Several tumor cells, including NB, switch to a
Figure 6.  DCL knockdown leads to a lower expression of mitochondrial-related genes.  Fold change of Cox7c (A), Cox6a2
(B), Ndufa1 (C) and Ndufa13 (D) mRNA expression in Dox-inducible NB cells (shDCL-2 or shDCL-3). Cells were treated with
doxycycline (Dox) or vehicle (Veh) for 72 hours. Fold change was calculated by normalization to the negative control (NC) Dox-
inducible NB cell line treated with Dox or Veh respectively. Error bars, s.e.m. **, P<0.01; ***, P<0.001.
doi: 10.1371/journal.pone.0075752.g006
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Figure 7.  DCL plays a role in mitochondrial activity.  Fold change in cytochrome c oxidase activity (A) and ATP synthesis (B) in
shDCL-2 and shDCL-3 Dox-inducible NB cells treated for 72 hours with doxycycline (Dox) or vehicle (Veh). (C) DCL and α-tubulin
expression in Dox-inducible NB cells treated with either Dox or Veh for 72 hours and subsequently transfected with DCL or empty
plasmids. Cells were lysed for western blotting analysis 48 hours after transfection. (D) DCL expression normalized to α-tubulin.
DCL expression is recovered in shDCL-2 and shDCL-3 cells after transfection with DCL plasmid (C-D). Fold change of cytochrome
c oxidase activity (E) and ATP synthesis (F) in shDCL-2 and shDCL-3 cells treated with either Dox or Veh (72 hours) and then
transfected with DCL or empty plasmid (48 hours). Fold changes were determined by normalizing to the negative control (NC) Dox-
inducible NB cell line treated with Dox or Veh respectively. Cytochrome c oxidase activity was investigated in isolated mitochondria.
Error bars, s.e.m. *, P<0.05; **, P<0.01; ***, P<0.001.
doi: 10.1371/journal.pone.0075752.g007
DCL in Mitochondrial Activity and NB Tumor Growth
PLOS ONE | www.plosone.org 12 September 2013 | Volume 8 | Issue 9 | e75752
Figure 8.  NB cells with DCL knockdown proliferate less in an energetic challenged environment.  (A-D) Cell proliferation in
Dox-inducible NB cell lines in the presence of low glucose (A) or high glucose (B) medium and treated with doxycycline (Dox) or
vehicle (Veh) for 72 hours. Cell proliferation in shDCL-2 (C) and shDCL-3 (D) cells 72 hours after starting the treatment with either
Dox or Veh and in the presence of low or high glucose medium. (E) Ratio in cell proliferation between Dox-inducible NB cells that
grew in low and high glucose medium. (F) Cell proliferation in shDCL-2 and shDCL-3 cells grown in high glucose medium, treated
with Dox or Veh for 72 hours and subsequently transfected with empty plasmid or DCL plasmid to recover DCL expression. NC,
negative control Dox-inducible NB cell lines. shDCL-2 and shDCL-3, Dox-inducible NB cell lines that express shRNA against DCL.
Error bars, s.e.m. *, P<0.05; **, P<0.01.
doi: 10.1371/journal.pone.0075752.g008
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preference for glucose metabolic processing by aerobic
glycolysis [17,18], a process rarely observed in non-
transformed cells, known as the Warburg effect [52,53].
Therefore, targeting the glycolytic process has been proposed
as therapeutic approach for cancer [49]. However, it was
observed that inhibition of glycolysis alone is not sufficient to
fully inhibit cell proliferation and tumor development because
cells are still able to produce ATP via OXPHOS [49]. Therefore,
combining glycolytic inhibitors with DCL loss-of-function could
be an effective approach for future NB treatment. In the same
line of reasoning, recent studies have demonstrated that
fasting cycles retard tumor growth and sensitize many cancer
cells to chemotherapy, including NB, by increasing oxidative
stress, caspase-3 cleavage, DNA damage and apoptosis [54].
Structurally, we demonstrate that the C-terminal portions of
DCL containing the second DCX and the S/P-rich domains are
required for cytochrome c oxidase activity and ATP synthesis.
Nevertheless, we were unable to separate the newly observed
regulation of mitochondrial activity from the previously
observed regulation of microtubule processing by DCL,
suggesting that these two different biological activities may be
linked. Indeed, there are indications that phosphorylation of the
S/P-rich domain of DCX family members is involved in
regulating cytoskeleton dynamics [14] and an intact
microtubule network together with MAPs is required for
mitochondrial transport throughout the cell [55,56] and to
regulate mitochondrial function [57,58,59,60]. It has been
shown that the interaction between MAP2 with the outer
mitochondrial membrane protein porin, induces alterations in
the physicochemical properties of porin environment [57,60].
The dual mitochondria and microtubule related functions have
been shown also in other MAPs, such as RASSF1 [61,62,63],
C19ORF5, also called MAP1S or RABP1 [61,62,63], and
SPD-3 [64].
The S/P-rich domain has been proposed as a protein
interaction platform [14]. DCL interact with the nuclear receptor
glucocorticoid receptor via the C-terminal SP-rich domain [13]
and therefore its presence might be required for regulation of
mitochondrial-related genes expression [51]. Furthermore, it
has been demonstrated that S/P-rich domain would be
phosphorylated by CDK5, protein kinase A (PKA), mitogen-
activated protein kinase (MAPK), c-Jun N-terminal kinases
(JNK) and phosphatases PP1 and PP2 [14,65,66]. Glycogen
synthase kinase (GSK-3) and MAPK extracellular signal-
regulated protein kinase 1 (ERK1) have been predicted to
phosphorylate S/P-rich domain as well [14]. These kinases that
regulate the dynamic phosphorylation state of the S/P-rich
domain present in several MAPs of the DCX family are known
Figure 9.  Serine/Proline (S/P)-rich and the second doublecortin (DCX)-domains of DCL are required for mitochondrial
activity regulation.  Cytochrome c oxidase activity (A) and ATP synthesis (B) in COS-1 cells transfected with empty vector, with
DCL full-length or with one of the different DCL fragments subcloned into pDsRed2-N1 vector is shown. The structure of DCL full-
length and the different DCL mutants is represented, indicating the DCX-domains and S/P-rich domain (SP). Error bars, s.e.m. *,
P<0.05.
doi: 10.1371/journal.pone.0075752.g009
DCL in Mitochondrial Activity and NB Tumor Growth
PLOS ONE | www.plosone.org 14 September 2013 | Volume 8 | Issue 9 | e75752
to play a role in cell proliferation [14,67]. Although we cannot
confirm that the link between DCL and mitochondrial activity is
related to mitochondria transport along microtubules, our study
clearly shows that the S/P-rich and the second DCX-domain
are required for proper mitochondrial activity in NB cells. These
domains are also present in other proteins of the DCX family,
such as DCX and DCLK2 [14]. It would be of interest to further
investigate if these proteins are also expressed in NB and
regulate mitochondrial activity and energy production.
Our results show, for the first time a role for DCL in NB tumor
growth in vivo. Our study reveals that DCL is involved in the
regulation of mitochondrial activity and energy production,
which are crucial processes for cell proliferation. Moreover, we
identify the DCX and S/P-rich domains as required for
regulation of mitochondrial activity. As these domains are also
present in other members of the DCX family, our results may
reveal a novel regulation mechanism involving energy supply
necessary for neuronal migration and proliferation of neuronal
progenitor cells. Furthermore, it may provide solid bases for
future studies such as potential combined therapeutic
approaches for NB.
Supporting Information
Figure S1.  DCL silencing results in down-regulation of
proliferation-related genes. Fold change in Ncl, Nenf, Pttg1
and S1006 mRNA expression in Dox-inducible NB cells
(shDCL-2 and shDCL-3) 72 hours after starting doxycycline
(Dox) or vehicle (Veh) treatment. Fold change was calculated
by normalizing to the negative control Dox-inducible NB cells
treated with Dox or Veh respectively. Error bars, S.E.M. *, P <
0.05; **, P < 0.01; ***, P < 0.001.
(TIF)
Figure S2.  Dox-diet induces shRNA expression in Dox-
inducible NB tumors. shRNA expression in the different Dox-
inducible NB tumors 14 days after injecting the NB cells
subcutaneously. Mice received doxycycline (Dox)- or vehicle
(Veh)-diet. NC, negative control Dox-inducible NB tumors.
shDCL-2 and shDCL-3, Dox-inducible NB tumors that express
a shRNA against DCL. N1E-115 cells, NB cell line used to
develop the Dox-inducible NB cells. RQ, relative quantification.
Error bars, S.E.M. ***, P < 0.001.
(TIF)
Figure S3.  The tumor histology revealed high
vascularization and necrotic areas. (A) Vascular counts per
microscopic field (200x magnification). Pictures are randomly
taken from three fields each at a magnification of ×200 (H&E
staining) from six independent sections. (B) Estimation of the
percentage of necrotic areas in the tumors. The necrotic areas
were quantified relative to total pixel density. Error bar, S.E.M.
*, P < 0.05.
(TIF)
Figure S4.  DCL colocalizes with mitochondria. (A) DCL
(green), mitochondria (red) and nuclei (Hoechst, blue) staining
in Dox-inducible NB cells treated with vehicle (Veh). (B)
Colocalization scores in Dox-inducible NB cells after 72 hours
doxycycline (Dox)- or Veh-treatment. Colocalization score was
quantified using ImageJ as describes previously (Fitzsimons et
al., 2008). NC, negative control Dox-inducible NB cells.
shDCL-2 and shDCL-3, Dox-inducible NB cell lines that
express a shRNA against DCL. Scale bars, 10 µm. Error bars,
S.E.M. *, P < 0.05.
(TIF)
Figure S5.  Recovery of DCL expression results in a
decrease in caspase-3 activity. Caspase-3 activity in Dox-
inducible NB cells (NC, shDCL-2 and shDCL-3) transfected
with DCL or empty plasmid is shown. Transfection was
performed 72 hours after starting doxycycline (Dox)- or vehicle
(Veh)-treatment and caspase-3 activity was investigated 48
hours after the transfection. Error bars, S.E.M. *, P < 0.05.
(TIF)
Figure S6.  Expression of DCL and DCL mutants in COS-1
cells transfected with the different DCL sequences
subcloned in pDsRed2-N1 vector. (A) Schematic
representation of DCL full-length (1) and the different DCL
mutants (2-7), showing the doublecortin domains (DCX-
domains) and Serine/Proline (S/P)-rich domain (SP). (B)
Western blotting results showing the expression of the fusion
proteins DCL full-length-DsRed2 and DCL truncations-DsRed2.
The expression of S/P-rich domain alone was not detectable,
as previously reported (Vreugdenhil et al. 2007).
(TIF)
Figure S7.  DCL full-length induces microtubule bundling
and is located in the nucleus and cytoplasm.
Immunofluorescence and colocalization of DCL full-length or
DCL mutants (red) and nucleus (Hoechst staining, blue) in
transfected COS-1 cells with different DCL sequences
subcloned into pDsRed2-N1 vector. DCL full-length and the
different DCL truncations were found present (+) or absent (-)
in the nucleus, cytoplasm and/or in microtubule bundling. The
second doublecortin (DCX) domain and the linker between this
domain and Serine/Proline (S/P)-rich domain (SP) were found
to be needed for microtubule bundling. +/-, present in few cells.
Scale bars, 40 µm.
(TIF)
Table S1.  (PDF)
Table S2.  (PDF)
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